Altogether, our results suggest that targeting RAGE might represent a promising approach to counteract loss of muscle mass and strength and prolong survival in cancer patients, and measuring serum levels of the RAGE ligands, S100B and HMGB1, in non‐cachectic patients might be of prognostic value toward the future occurrence of cachexia. This evidence concerns the gene S100B and Cachexia.